Key facts
- Notable investors include ZGC Science City, Capital Science and Technology Development Group, Panacea Capital (California).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Biofront Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Biofront Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biofront Therapeutics
Developer of drug discovery platforms intended for multinational pharmaceutical companies, biotech investors, and clinical research institutions. The company's drug discovery platform integrates early de-risking capabilities, proprietary wet-lab technologies, and a multidisciplinary team experienced, thereby enabling partners to gain access to high-quality preclinical candidates and scalable innovation pipelines.
- Sector
- Information Technology
- HQ
- Beijing, China
- Founded
- 2018
- Employees
- 6
- Website
- biofronttherapeutics.com/
- Ownership
- Privately Held (backing)
Biofront Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biofront Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biofront Therapeutics in its N-PORT filings yet. We sweep new filings monthly.